Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SEMA4C as a Relapse Biomarker in Breast Cancer

NCT03663153 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT03663153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03663153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SEMA4C as a Relapse Biomarker in Breast Cancer
Lead sponsor
Tongji Hospital
Phase
Observational
Overall status
Unknown status
Start date
September 1, 2022
Completion date
August 1, 2026
Enrollment
4,200 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer